Quest Diagnostics Net Worth
Quest Diagnostics Net Worth Breakdown | DGX |
Quest Diagnostics Net Worth Analysis
Quest Diagnostics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Quest Diagnostics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Quest Diagnostics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Quest Diagnostics' net worth analysis. One common approach is to calculate Quest Diagnostics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Quest Diagnostics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Quest Diagnostics' net worth. This approach calculates the present value of Quest Diagnostics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Quest Diagnostics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Quest Diagnostics' net worth. This involves comparing Quest Diagnostics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Quest Diagnostics' net worth relative to its peers.
Enterprise Value |
|
To determine if Quest Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Quest Diagnostics' net worth research are outlined below:
| Quest Diagnostics has a strong financial position based on the latest SEC filings | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| On 21st of October 2024 Quest Diagnostics paid $ 0.75 per share dividend to its current shareholders | |
| Latest headline from finance.yahoo.com: 6.1 Bn Dietary Supplement Testing Services Global Market Opportunities and Strategies to 2033 Contaminant Testing Platforms, Adulteration Panel Analysis, AI-Driven Platforms for Improved Testing |
Quest Diagnostics Quarterly Good Will |
|
Quest Diagnostics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Quest Diagnostics Incorporated. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Quest Diagnostics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Quest Diagnostics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Quest Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Quest Diagnostics Incorporated backward and forwards among themselves. Quest Diagnostics' institutional investor refers to the entity that pools money to purchase Quest Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2024-06-30 | 1.8 M | Goldman Sachs Group Inc | 2024-06-30 | 1.7 M | Jpmorgan Chase & Co | 2024-06-30 | 1.5 M | Wells Fargo & Co | 2024-06-30 | 1.5 M | Fiduciary Management, Inc. Of Milwaukee | 2024-09-30 | 1.4 M | Norges Bank | 2024-06-30 | 1.3 M | Fmr Inc | 2024-09-30 | 1.1 M | Northern Trust Corp | 2024-09-30 | 1 M | Legal & General Group Plc | 2024-06-30 | 959.6 K | Vanguard Group Inc | 2024-09-30 | 14 M | Blackrock Inc | 2024-06-30 | 10.1 M |
Follow Quest Diagnostics' market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 18.26 B.Market Cap |
|
Project Quest Diagnostics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.17 | 0.14 | |
| Return On Capital Employed | 0.10 | 0.10 | |
| Return On Assets | 0.06 | 0.04 | |
| Return On Equity | 0.14 | 0.08 |
When accessing Quest Diagnostics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Quest Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Quest Diagnostics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Quest Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Quest Diagnostics Incorporated. Check Quest Diagnostics' Beneish M Score to see the likelihood of Quest Diagnostics' management manipulating its earnings.
Evaluate Quest Diagnostics' management efficiency
Quest Diagnostics has Return on Asset of 0.0566 % which means that on every $100 spent on assets, it made $0.0566 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1322 %, implying that it generated $0.1322 on every 100 dollars invested. Quest Diagnostics' management efficiency ratios could be used to measure how well Quest Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.14 in 2024. Return On Capital Employed is likely to drop to 0.10 in 2024. At this time, Quest Diagnostics' Other Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.99 in 2024, whereas Total Assets are likely to drop slightly above 8.5 B in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 57.30 | 60.17 | |
| Tangible Book Value Per Share | (22.15) | (21.04) | |
| Enterprise Value Over EBITDA | 11.62 | 7.35 | |
| Price Book Value Ratio | 2.45 | 3.00 | |
| Enterprise Value Multiple | 11.62 | 7.35 | |
| Price Fair Value | 2.45 | 3.00 | |
| Enterprise Value | 9.7 B | 10.2 B |
At Quest Diagnostics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 2.5647 | Revenue 9.5 B | Quarterly Revenue Growth 0.084 | Revenue Per Share 85.744 | Return On Equity 0.1322 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Quest Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Quest Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Quest Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Karthik Kuppusamy over three weeks ago Disposition of 1775 shares by Karthik Kuppusamy of Quest Diagnostics at 156.9156 subject to Rule 16b-3 | ||
Michael Deppe over two months ago Disposition of tradable shares by Michael Deppe of Quest Diagnostics at 125.02 subject to Rule 16b-3 | ||
Sam Samad over three months ago Disposition of 656 shares by Sam Samad of Quest Diagnostics at 126.36 subject to Rule 16b-3 | ||
John Ziegler over a year ago Sale by John Ziegler of 1953 shares of Quest Diagnostics |
Quest Diagnostics Corporate Filings
F4 | 7th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 23rd of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 22nd of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 16th of August 2024 Prospectus used primarily for registering securities for public sale. | ViewVerify |
Quest Diagnostics Earnings per Share Projection vs Actual
Quest Diagnostics Corporate Directors
| Gail Wilensky | Independent Director | Profile | |
| Wright Lassiter | Independent Director | Profile | |
| Gary Pfeiffer | Independent Director | Profile | |
| Vicky Gregg | Independent Director | Profile |
Additional Tools for Quest Stock Analysis
When running Quest Diagnostics' price analysis, check to measure Quest Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest Diagnostics is operating at the current time. Most of Quest Diagnostics' value examination focuses on studying past and present price action to predict the probability of Quest Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest Diagnostics' price. Additionally, you may evaluate how the addition of Quest Diagnostics to your portfolios can decrease your overall portfolio volatility.